FDA Misses Deadline on Savara’s Inhaled Drug for Rare Lung Disease

The FDA will not meet the Nov. 22, 2026 deadline for Savara’s molgramostim BLA for autoimmune PAP. The review is ongoing with no new date set.

FDA Misses Deadline on Savara’s Inhaled Drug for Rare Lung Disease
Credit: Savara
Already have an account? Sign in.